Diabetes patients are more vulnerable to COVID-19 infections, which can cause serious respiratory conditions. In this study, the effect of the antiviral medication with molnupiravir and favipiravir was compared in COVID-19 patients with underlying diabetes. The current investigation included a cohort of 100 people who had been diagnosed with diabetes, had a SARS-CoV-2 infection, and had been admitted sequentially. The antiviral drugs were administered to these patients according to regional recommendations: favipiravir was administered for 10 days for group F (51 instances), while molnupiravir was administered for 5 days to group M (49 cases). Compared to group M, group F showed a higher mean hospitalisation rate (11.29 ± 2.27 vs. 7.14 ± 3.16, P < 0.001). At the end of treatment, group M’s risk score for severe evolution was less statistically significant (156.29 ± 61.32; 160.59 ± 59.41, P < 0.001). When molnupiravir was administered instead of favipiravir, the number of deaths among COVID-19 patients was reduced [2 (4.08%) vs. 9 (17.65%), P = 0.034]. Molnupiravir outperformed favipiravir when it came to treating SARS-CoV-2 infections in diabetic patients. Diagnosing or treating diabetes is essential to halting the critical course of COVID-19 in individuals. Its promise in the treatment of SARS-CoV-2-infected individuals requires more investigation.
